The role of PPARγ in osteoclastogenesis, osteoclast differentiation and function.

The role of PPARγ in osteoclastogenesis, osteoclast differentiation and function. - PPARγ and osteoclastogenesis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37089

Enrollment

Registered

2012-12-04

Start date

2012-12-04

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis porous bones

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: The healthy volunteer is willing and able to provide written informed consent prior to study-related procedures. The healthy volunteer is >= 18 years of age.

Exclusion criteria

Exclusion criteria: Use of anticoagulants

Design outcomes

Primary

Measure	Time frame
Osteoclasts will be cultured under different conditions (control, with PPARγ- agonist, with PPARγ-agonist). The overall objective of this project is to gain more inside into the role of PPARγ in osteoclastogenesis and osteoclast differentiation. This will be done by assessing the following: - Osteoclast formation (by assessing the formation of tartrate-resistent acid phosphatase positive multinucleated cells (TRACP+ MNCs)) - Osteoclast activity (by analyzing bone resorption as described previously) - Osteoclast differentiation (will be quantified by RNA expression of PPARγ, PGC1β, RANK, c-fms, c-fos, NFATc1, TRACP, Cathepsine K, calcitonin receptor, DC-STAMP) - Osteoclast function (by in vitro resorption of bone slices)	—

Measure

Time frame

Osteoclasts will be cultured under different conditions (control, with PPARγ- agonist, with PPARγ-agonist). The overall objective of this project is to gain more inside into the role of PPARγ in osteoclastogenesis and osteoclast differentiation. This will be done by assessing the following: - Osteoclast formation (by assessing the formation of tartrate-resistent acid phosphatase positive multinucleated cells (TRACP+ MNCs)) - Osteoclast activity (by analyzing bone resorption as described previously) - Osteoclast differentiation (will be quantified by RNA expression of PPARγ, PGC1β, RANK, c-fms, c-fos, NFATc1, TRACP, Cathepsine K, calcitonin receptor, DC-STAMP) - Osteoclast function (by in vitro resorption of bone slices)

—

Countries

Netherlands

Outcome results